Thank You For Submiting Feedback!
United States District Court for the Central District of California
March 24, 2020, Decided; March 24, 2020, Filed
CIVIL MINUTES - GENERAL
PROCEEDINGS (in chambers): ORDER RE: DEFENDANT'S MOTION FOR JUDGMENT AS A MATTER OF LAW PURSUANT TO FED. R. CIV. P. 50(B) AND/OR A NEW TRIAL PURSUANT TO FED. R. CIV. P. 59 [ECF No. 659]
[Portions of the parties' briefing filed in support of and in opposition to the motion ruled upon in this Order were filed under seal. The parties are expected to file a joint report within five days of this ruling proposing redactions of any confidential material. If the parties fail to file a joint report, this Order will be publicly issued as-is.]
This matter comes before the Court on Defendant Kite Pharma, Inc.'s ("Defendant" or "Kite") Motion for Judgment as a Matter of Law Pursuant to Fed. R. Civ. P. 50(b) and/or a New Trial Pursuant to Fed. R. Civ. P. 59 ("JMOL") filed on January 21, 2020. (JMOL, ECF No. 659.1 ) Plaintiffs Juno Therapeutics, Inc. ("Juno") and Sloan Kettering Institute for Cancer Research ("SKI") (collectively, "Plaintiffs") filed their Opposition to Defendant's Motion for Judgment as a Matter of Law and/or a New Trial ("Opposition" or "Opp.") on February 10, 2020. (Opp., ECF Nos. 673.2 ) Defendant [*2] filed its Reply in Support of a Motion for Judgment as a Matter of Law Pursuant to Fed. R. Civ. P. 50(b) and/or a New Trial Pursuant to Fed. R. Civ. P. 59 ("Reply") on February 24, 2020. (Reply, ECF No. 699.3 ) In setting the post-trial briefing schedule, the Court indicated that it would take the matter under submission following the filing of reply motions. (Order, ECF No. 639 at 5; see also Fed. R. Civ. P. 78(b).) For the following reasons, the Court DENIES Defendant's Motion for Judgment as a Matter of Law Pursuant to Fed. R. Civ. P. 50(b) and/or a New Trial Pursuant to Fed. R. Civ. P. 59 [ECF No. 659].
Full case includes Shepard's, Headnotes, Legal Analytics from Lex Machina, and more.
2020 U.S. Dist. LEXIS 259570 *; 2020 WL 10460622
Juno Therapeutics, Inc., et al. v. Kite Pharma, Inc.
Reply, scFvs, patent, genus, new trial, infringement, written description, amino acid, verdict form, upfront, damages, license, argues, sequence, invalid, willful, matter of law, correction, invention, denies, non-infringing, disclosure, figures, specification, witnesses, billion, minutes, parties, weight of the evidence, negotiation